NUMD (Nu-Med Plus) Debt-to-Equity : -0.49 (As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Nu-Med Plus Debt-to-Equity?

Nu-Med Plus's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.10 Mil. Nu-Med Plus's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.00 Mil. Nu-Med Plus's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $-0.21 Mil. Nu-Med Plus's debt to equity for the quarter that ended in Sep. 2024 was -0.49.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Nu-Med Plus's Debt-to-Equity or its related term are showing as below:

NUMD' s Debt-to-Equity Range Over the Past 10 Years
Min: -11.76 Med: -0.64 Max: 7.38
Current: -0.49

During the past 13 years, the highest Debt-to-Equity Ratio of Nu-Med Plus was 7.38. The lowest was -11.76. And the median was -0.64.

NUMD's Debt-to-Equity is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.21 vs NUMD: -0.49

Nu-Med Plus Debt-to-Equity Historical Data

The historical data trend for Nu-Med Plus's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nu-Med Plus Debt-to-Equity Chart

Nu-Med Plus Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.64

0.04

-0.06

-1.59

-0.68

Nu-Med Plus Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial															-0.76	-0.68	-0.59	-0.54	-0.49

Competitive Comparison of Nu-Med Plus's Debt-to-Equity

For the Medical Devices subindustry, Nu-Med Plus's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nu-Med Plus's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nu-Med Plus's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Nu-Med Plus's Debt-to-Equity falls into.

Nu-Med Plus Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Nu-Med Plus's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.1	+	0)	/	-0.147
	=	-0.68

Nu-Med Plus's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.1	+	0)	/	-0.205
	=	-0.49

Nu-Med Plus (OTCPK:NUMD) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Nu-Med Plus Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Nu-Med Plus's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Nu-Med Plus Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nu-Med Plus Inc (OTCPK:NUMD) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

640 Belle Terre Road, Building 2 E Port, Jefferson, NY, USA, 11777

Website

https://www.nu-medplus.com

Nu-Med Plus Inc is an medical device company principally engaged in the design, innovation, development, enhancement, and commercialization of beginning, early, and selective later-stage quality medical devices. It focuses on the formulation of Nitric Oxide powder, which is a desktop generator device which delivers inhaled Nitric Oxide to replace expensive pressurized canisters and a mobile rechargeable device to deliver inhaled Nitric Oxide gas to offer solutions to hospitals, health systems and medical community throughout the world.

Executives

William C Hayde	director, officer: CEO	76 CLIFF ROAD, BELLE TERRE NY 11777
Wendy P. Smith	10 percent owner	P. O. BOX 1374, SALT LAKE CITY UT 84110
Brett J. Earl	director, officer: VP of Medical Marketing	P.O. BOX 729, MORGAN UT 84050
Mark Edward Christensen	officer: CFO, Sec, Treas, Prin Acct Off	455 E. 500 S., SUITE 207, SALT LAKE CITY UT 84111
Thomas A Tait	10 percent owner	514 AMERICAS WAY #5556, BOX ELDER SD 57719
Craig Morrison	director, 10 percent owner, officer: Vice President of Technology	975 NORTH TERRACE DRIVE, PROVO UT 84604
William G Moon	director, 10 percent owner, officer: Vice President of Operations	1266 SOUTH 1380 WEST, OREM UT 84058
Jeffrey Lynn Robins	director, 10 percent owner, officer: CEO	455 EAST 500 SOUTH, SUITE #205, SALT LAKE CITY UT 84111